论文部分内容阅读
为探讨卵巢恶性肿瘤组织中ＣＤ４４Ｖ３的表达及其临床意义，用免疫组织化学和ＲＴ－ＰＣＲ方法，检测４１例恶性卵巢肿瘤、２０例良性卵巢肿瘤和２１例正常卵巢组织中ＣＤ４４Ｖ３基因及基因蛋白的表达情况，并分析相关的临床病理因素。结果：ＣＤ４４Ｖ３表达阳性率恶性组显著高于良性组和正常组（均Ｐ＜０．０５）；有转移者ＣＤ４４Ｖ３阳性率显著高于无转移者（Ｐ＜０．０１），转移灶阳性率高于原发灶（Ｐ＝０．０１）；ＣＤ４４Ｖ３阳性表达者近期疗效比阴性者差（Ｐ＜０．０５）；ＣＤ４４Ｖ３阳性表达率与临床期别有一定关系，但与病理类型、组织学级别无关（Ｐ＞０．０５）。表明，ＣＤ４４Ｖ３与肿瘤的发生、发展、卵巢恶性肿瘤的浸润和转移、以及近期疗效有关，可以作为预测肿瘤转移潜能和评估预后的指标
To investigate the expression of CD44V3 in ovarian cancer and its clinical significance, immunohistochemistry and RT-PCR were used to detect the expression of CD44V3 gene and protein in 41 cases of malignant ovarian tumor, 20 cases of benign ovarian tumor and 21 cases of normal ovarian tissue Express the situation, and analyze the related clinicopathological factors. Results: The positive rate of CD44V3 in malignant group was significantly higher than that in benign group and normal group (all P <0.05). The positive rate of CD44V3 in metastasis was significantly higher than that in non-metastasis (P <0.01) (P = 0.01). The positive rate of CD44V3 positive expression was lower than negative (P <0.05). The positive rate of CD44V3 was related to the clinical stage, but not with the pathological type, histological grade Not related (P> 0.05). These results indicate that CD44V3 is associated with tumorigenesis and development, infiltration and metastasis of ovarian cancer, and short-term curative effect, which can be used as an index to predict tumor metastasis potential and evaluate prognosis